Results 231 to 240 of about 92,697 (378)

Allergic Sensitization to Inhalant Allergens in the Upper Respiratory Tract—the B Cell Side

open access: yesAllergy, EarlyView.
ABSTRACT Allergic diseases are on the rise worldwide, driven by respiratory epithelial barrier dysfunction that promotes sensitization to inhalant allergens such as pollen, dust mites, pet dander, and fungal spores. These antigens trigger IgE‐mediated immune responses that lead to diseases such as allergic rhinitis (AR) and asthma.
Ola Grimsholm   +9 more
wiley   +1 more source

Exhaled Volatile Organic Compounds Identify Allergic Patients Among Individuals With Chronic Rhinitis

open access: yesAllergy, EarlyView.
Exhaled decane and nonadecane discriminate allergic (AR + LAR) from non‐allergic (NAR + HC) subjects among individuals with chronic rhinitis. LAR patients display higher levels of exhaled nonadecane than NAR individuals at baseline. Subjects with FeNO≥ 25 ppb have higher levels of exhaled decane, nonanal, and styrene than individuals with FeNO < 25 ppb
Rosa Alba Sola‐Martinez   +9 more
wiley   +1 more source

Association Between Endoscopic, Radiologic and Patient-reported Chronic Rhinosinusitis with Nasal Polyps [PDF]

open access: diamond, 2019
Annika Luukkainen   +10 more
openalex   +1 more source

A Case for Anti‐IgE Vaccination

open access: yesAllergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff   +3 more
wiley   +1 more source

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

open access: yesAllergy, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang   +37 more
wiley   +1 more source

Home - About - Disclaimer - Privacy